NEW DELHI: Drug major Lupin expects to launch nearly 25 products in the US market in 2016-17 that the company expects to be the key driver for its revenue growth, going forward.”We expect to launch a good number of products between India and Gavis (US). We are hoping to launch 25 plus products, FDA permitting. So, a good number of launches that we expect for the year,” Lupin CEO Vinita Gupta said in a conference call.